Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $6.45 and last traded at $6.45, with a volume of 1254 shares. The stock had previously closed at $6.63.
A number of research analysts recently commented on NAUT shares. Jefferies Financial Group began coverage on shares of Nautilus Biotechnology in a research note on Tuesday, July 13th. They issued a “buy” rating and a $13.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Nautilus Biotechnology in a research note on Wednesday, August 4th. They set a “neutral” rating and a $10.00 price target for the company.
The stock’s 50 day moving average is $7.70.
In other news, General Counsel Matthew B. Murphy acquired 5,000 shares of the company’s stock in a transaction on Friday, August 13th. The stock was bought at an average cost of $7.56 per share, with a total value of $37,800.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Anna Mowry acquired 17,500 shares of the company’s stock in a transaction on Thursday, August 12th. The shares were purchased at an average cost of $7.71 per share, with a total value of $134,925.00. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 47,777 shares of company stock valued at $367,204.
Several institutional investors and hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC bought a new stake in shares of Nautilus Biotechnology in the second quarter valued at about $12,027,000. Perceptive Advisors LLC bought a new position in Nautilus Biotechnology in the second quarter worth about $90,002,000. RA Capital Management L.P. bought a new position in Nautilus Biotechnology in the second quarter worth about $24,961,000. Skye Global Management LP bought a new position in Nautilus Biotechnology in the second quarter worth about $354,000. Finally, Franklin Resources Inc. bought a new position in Nautilus Biotechnology in the second quarter worth about $5,050,000. 26.60% of the stock is owned by hedge funds and other institutional investors.
About Nautilus Biotechnology (NASDAQ:NAUT)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome.
Featured Story: What is Depreciation?
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.